Free Prostate-Specific Antigen Provides More Precise Data on Benign Prostate Volume Than Total Prostate-Specific Antigen in Korean Population
1
조회
0
다운로드
0
인용
0
참고문헌
초록
Purpose: To investigate the efficacy of total prostate-specific antigen (tPSA) and free prostate-specific antigen (fPSA) for the estimation of prostate volume (PV) in pathologically-proven benign prostatic hyperplasia (BPH) patients. Methods: From January 2010 to March 2013, 165 Korean men with a PSA less than 10 ng/mL who were diagnosed without prostate cancer by prostate biopsy were enrolled. Patients were classified into three age groups: ≤60, 61–70, and >70 years old. The results were organized to estimate and compare the ability of serum tPSA and fPSA to assess the PV. Results: Enrolled patients had a median age of 63.5 years (44 to 80), a median tPSA of 5.72 ng/mL, a median fPSA of 0.98 ng/mL and a median PV of 53.68 mL, respectively. Among the associations between tPSA, fPSA, age, and PV, the highest correlation was verified between fPSA and PV (r=0.377, P<0.0001); the correlation coefficient between tPSA and PV was much lower (r=0.262, P<0.001). All stratified age cohorts showed the same findings. The ROC curves (for PV greater than 30, 40, and 50 mL) showed that fPSA (area under the curve [AUC]=0.781, 0.718, and 0.700) outperformed tPSA (AUC=0.657, 0.583, and 0.67) in its ability to predict clinically significant PV enlargement. Conclusion: Both tPSA and fPSA significantly correlated with PV in Korean men, while the correlation efficiency between fPSA and PV was more powerful. fPSA may be a useful tool in making therapeutic decisions and follow-up management in BPH patients.
Abstract
Purpose: To investigate the efficacy of total prostate-specific antigen (tPSA) and free prostate-specific antigen (fPSA) for the estimation of prostate volume (PV) in pathologically-proven benign prostatic hyperplasia (BPH) patients. Methods: From January 2010 to March 2013, 165 Korean men with a PSA less than 10 ng/mL who were diagnosed without prostate cancer by prostate biopsy were enrolled. Patients were classified into three age groups: ≤60, 61–70, and >70 years old. The results were organized to estimate and compare the ability of serum tPSA and fPSA to assess the PV. Results: Enrolled patients had a median age of 63.5 years (44 to 80), a median tPSA of 5.72 ng/mL, a median fPSA of 0.98 ng/mL and a median PV of 53.68 mL, respectively. Among the associations between tPSA, fPSA, age, and PV, the highest correlation was verified between fPSA and PV (r=0.377, P<0.0001); the correlation coefficient between tPSA and PV was much lower (r=0.262, P<0.001). All stratified age cohorts showed the same findings. The ROC curves (for PV greater than 30, 40, and 50 mL) showed that fPSA (area under the curve [AUC]=0.781, 0.718, and 0.700) outperformed tPSA (AUC=0.657, 0.583, and 0.67) in its ability to predict clinically significant PV enlargement. Conclusion: Both tPSA and fPSA significantly correlated with PV in Korean men, while the correlation efficiency between fPSA and PV was more powerful. fPSA may be a useful tool in making therapeutic decisions and follow-up management in BPH patients.
참고문헌 (18)
- Madersbacher S, "EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines)", Eur Urol, 46, pp.547~554 (2004)
- Stenman UH, "A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer", Cancer Res, 51, pp.222~226 (1991)
- Lilja H, "Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin", Clin Chem, 37, pp.1618~1625 (1991)
- Hong SJ, "Identification of baseline clinical factors which predict medical treatment failure of benign prostatic hyperplasia: an observational cohort study", Eur Urol, 44, pp.94~99 (2003)
- McConnell JD, "The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia", N Engl J Med, 349, pp.2387~2398 (2003)
- Jacobsen SJ, "Natural history of prostatism: risk factors for acute urinary retention", J Urol, 158, pp.481~487 (1997)
- Roehrborn CG, "Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group", Urology, 53, pp.473~480 (1999)
- Torp-Pedersen S, "Transrectal prostatic ultrasonography: equipment, normal findings, benign hyperplasia and cancer", Scand J Urol Nephrol Suppl, 107, pp.19~25 (1988)
- Roehrborn CG, "Correlation between prostate size estimated by digital rectal examination and measured by transrectal ultrasound", Urology, 49, pp.548~557 (1997)
- Smith DS, "Longitudinal screening for prostate cancer with prostate-specific antigen", JAMA, 276, pp.1309~1315 (1996)
- Boyle P, "Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials", Urology, 48, pp.398~405 (1996)
- Roehrborn CG, "Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia", Urology, 53, pp.581~589 (1999)
- Bohnen AM, "Serum prostate-specific antigen as a predictor of prostate volume in the community: the Krimpen study", Eur Urol, 51, pp.1645~1652 (2007)
- Parsons JK, "Complexed prostate specific antigen (PSA) reduces unnecessary prostate biopsies in the 2.6-4.0 ng", mL range of total PSA, 2004, pp.94, 47~50
- Parsons JK, "Applying complexed prostate-specific antigen to clinical practice", Urology, 63, pp.815~818 (2004)
- Morote J, "Prediction of prostate volume based on total and free serum prostate-specific antigen: is it reliable?", Eur Urol, 38, pp.91~95 (2000)
- Canto EI, "Serum BPSA outperforms both total PSA and free PSA asa predictor of prostatic enlargement in men without prostate cancer", Urology, 63, pp.905~910 (2004)
- Mao Q, "Relationships between total", free prostate-specific antigen and prostate volume in Chinese men with biopsy-proven benign prostatic hyperplasia, 2009, pp.41, 761~766